Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cerilliant
McKesson
Medtronic
Fuji
Boehringer Ingelheim
Federal Trade Commission
Daiichi Sankyo
US Department of Justice

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: RE42152

« Back to Dashboard

Which drugs does patent RE42152 protect, and when does it expire?

Patent RE42152 protects MOZOBIL and is included in one NDA.

This patent has thirty-one patent family members in twenty-three countries.
Summary for Patent: RE42152
Title:Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
Abstract:Polyamine macrocyclic compounds, e.g. of 10 to 15 ring members and 3 to 6 ring amine nitrogens, linked through methylene groups to an aromatic moiety, show high selective activity against HIV.
Inventor(s): Bridger; Gary J. (Bellingham, WA), Padmanbhan; Sreenivasan (Exton, PA), Skerlj; Renato (Newton, MA), Thornton; David M. (Reading, GB)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:12/192,704
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent RE42152

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: RE42152

PCT Information
PCT FiledDecember 16, 1992PCT Application Number:PCT/GB92/02334
PCT Publication Date:June 24, 1993PCT Publication Number: WO93/12096

Non-Orange Book US Patents Family Members for Patent RE42152

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,583,131 Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent RE42152

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 273964 ➤ Try a Free Trial
Australia 3165593 ➤ Try a Free Trial
Australia 661086 ➤ Try a Free Trial
Canada 2125978 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
US Department of Justice
Baxter
Merck
Teva
Deloitte
US Army
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.